Salvage Lung Resection for Non-small Cell Lung Cancer After Stereotactic Body Radiotherapy in Initially Operable Patients  by Chen, Fengshi et al.
BRIEF REPORT
Salvage Lung Resection for Non-small Cell Lung Cancer
After Stereotactic Body Radiotherapy in Initially Operable
Patients
Fengshi Chen, MD, PhD,* Yukinori Matsuo, MD, PhD,† Akihiko Yoshizawa, MD, PhD,‡
Toshihiko Sato, MD, PhD,* Hiroaki Sakai, MD, PhD,* Toru Bando, MD, PhD,*
Kenichi Okubo, MD, PhD,* Keiko Shibuya, MD, PhD,† and Hiroshi Date, MD, PhD*
Background: Stereotactic body radiotherapy (SBRT) has emerged
as a curative treatment for medically inoperable patients with early-
stage non-small cell lung cancer (NSCLC). Since NSCLC recurs
locally in 10% of the patients treated with SBRT, salvage lung
resection after SBRT may be considered in these cases. To further
understand the indications for salvage surgery and the pathogenesis
of tumor recurrence in these patients, we retrospectively reviewed
cases treated at our institution.
Methods: SBRT has been performed in patients with early-stage
NSCLC at Kyoto University Hospital. We encountered 5 patients
who underwent salvage lung resection for NSCLC after SBRT.
Results: All the patients were initially operable, but they chose
SBRT. After SBRT, the tumors shrank initially in all patients, but
increased in size within 18 months of SBRT in the case of 4 patients.
During surgical extirpation, we did not find any significant SBRT-
related adhesions in any of the patients.
Conclusions: We have successfully treated 5 patients who under-
went salvage lung resection for early-stage NSCLC after SBRT. We
found that surgical resection was feasible after SBRT.
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(J Thorac Oncol. 2010;5: 1999–2002)
Stereotactic body radiotherapy (SBRT) is a recently devel-oped radiotherapeutic method for early-stage non-small
cell lung cancer, and failure of local control is estimated to
occur in around 10% of the patients treated with SBRT. It has
been reported that some patients develop local recurrence
after SBRT and are then considered for salvage surgical
resection.1 In this study, we retrospectively reviewed five
such cases treated at our institution to further understand the
indications for salvage lung resection for non-small cell lung
cancer after SBRT.
PATIENTS AND METHODS
Since 1998, three-dimensional conformal SBRT has
been performed in patients with solitary lung tumors at the
Kyoto University Hospital. The indications for SBRT have
been already described elsewhere.2,3 In short, the indications
of SBRT in patients with lung cancer were as follows: (1)
solitary tumor of less than 4 cm in diameter; (2) inoperable
patients or patients refusing surgery; (3) performance status
2; and (4) a peripheral tumor in which dose constraints of
mediastinal surrounding organs were maintained. During July
1998 and March 2008, SBRT was performed for 144 patients
with primary lung cancer. Local recurrence was observed in
24 patients (16.7%) with a median follow-up of 31.5 months.
Chemotherapy was administered for the local recurrence in
nine patients including one patient with chemoradiotherapy.
Best supportive care was chosen for 10 patients. Five patients
were salvaged with surgery. Details on planning procedures
were described in our previous article.4 In summary, the
internal target volume (ITV) was defined based on two
imaging modalities: computed tomography (CT) with a slow-
scan technique and x-ray fluoroscopy for evaluation of mo-
tion ranges of the tumor. When the ITV delineated on the
slow-scan CT was insufficient to cover the tumor motion
observed in the fluoroscopy, the ITV was manually expanded.
The planning target volume for SBRT was set with a margin
of 5 mm to the ITV. The total radiation dose was 48 Gy at the
isocenter with a daily fractional dose of 12 Gy, except the
initial three patients with 40 Gy. The irradiation was admin-
istered during a period of 1 to 2 weeks. The biologic effective
dose was 105.6 Gy at the isocenter. The patients were
followed up every 2 to 3 months after SBRT. When local
recurrence was suspected from follow-up CT images, an
fluorodeoxyglucose-positron emission tomography scan was
performed, and radiology peer review was undertaken. If
local recurrence without distant metastasis was considered
highly probable on the basis of the review, the patient was
referred to a thoracic surgeon for possible salvage resection.
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and patient consent was waived because the study was retro-
spective and ensured anonymity.
RESULTS
In all the patients, a final decision for selecting SBRT
was made as per the patient’s preference (Table 1). Four
patients had poor pulmonary functional reserve due to
chronic obstructive pulmonary disease (COPD). According to
GOLD classification of COPD, two patients were classified
into stage IIa and one was stage IIb, whereas the rest patient,
who had been initially classified stage I and had been referred
to our hospital, became stage 0 after the medical treatment of
COPD. After SBRT, the tumor shrank initially in all patients.
The typical chest CT with clinical course was described in
Figure 1. Continuous increase of the tumor in size is strongly
indicative of tumor relapse after SBRT, although the patho-
FIGURE 1. Clinical course of patient
1. A, Chest computed tomography
(CT) at stereotactic body radiotherapy
(SBRT) showed a mass with 36 mm in
diameter in the left upper lobe. B,
Chest CT 5 months after SBRT demon-
strated remarkable tumor shrinkage. C,
Chest CT 10 months after SBRT re-
vealed an apparent tumor relapse.
TABLE 1. Patient Characteristics at Stereotactic Body Radiotherapy (SBRT)
Patients
Age (yr)/
Gender
c-TNM
Stage
Tumor
Size (mm) Histology Reason for SBRT
Clinical Course
After SBRT
1 63/M T2N0M0 36 SQ COPD (%FEV1 49%), DM, HD,
and patient preference
Shrank but increased 10 mo
after SBRT
2 75/M T1N0M0 28 AD COPD (%FEV1 57%), DM,
angina, and patient preference
Shrank but increased 10 mo
after SBRT
3 70/M T1N0M0 24 Unknown Patient preference Shrank but increased 89 mo
after SBRT
4 84/M T1N0M0 19 AD or LCNEC COPD (%FEV1 61%) and patient
preference
Shrank but increased 8 mo
after SBRT
5 75/M T1N0M0 10 SQ COPD (%FEV1 101%a) and
patient preference
Shrank but increased 16 mo
after SBRT
a %FEV1 was initially 77% at referral to our hospital, but finally increased up to 101% after intensive treatment with drugs and rehabilitation.
AD, adenocarcinoma; COPD, chronic obstructive pulmonary disease; DM, diabetes mellitus; HD, hemodialysis; LCNEC, large cell neuroendocrine carcinoma; M, male; NSCLC,
non-small cell lung cancer; SQ, squamous cell carcinoma; SBRT, stereotactic body radiotherapy; %FEV1, percentage of forced expiratory volume in 1 s to a predicted value.
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logic diagnosis was not confirmed before surgical extirpation
in all patients. At the time of recurrence, fluorodeoxyglucose-
positron emission tomography scan revealed high uptake in
the relapsed tumor in all patients. There were no apparent
adverse complications related to SBRT in all five patients.
The preoperative condition of the patients was almost
the same as that at the time of SBRT (Table 2). To be more
specific, pulmonary function tests did not show any deterio-
ration after SBRT in four patients who had COPD. In detail,
the mean forced expiratory volume in 1 second (FEV1) was
67% of the predicted value before SBRT in four patients with
COPD, whereas FEV1 was 73% of the predicted value before
surgery. As salvage surgery, lobectomy with lymph node
dissection was performed in all patients. Surgical extirpation
did not confirm significant pleural adhesions in any patient.
Furthermore, because there was no apparent SBRT-related
change in the pulmonary structure, dissection around the
vessels and bronchus was performed without difficulties.
There were no complications during surgery, and postopera-
tive course was also uncomplicated in all cases.
Histologically, three patients (patients 1, 2, and 5) were
diagnosed as having squamous cell carcinoma. Patient 3,
whose histologic subtype was not confirmed before SBRT,
was diagnosed as having adenocarcinoma. Patient 4 was
diagnosed as having large cell neuroendocrine carcinoma. All
patients were pathologic stage I with a mean tumor size of 34
mm in diameter, ranging from 25 to 50 mm. The tumor size
of four patients increased again within 18 months of SBRT.
In three of the four patients (patients 1, 4, and 5), pathologic
examination revealed that viable cancer cells were present in
the center of the tumor with surrounding fibrotic tissue caused
by SBRT (Figure 2). In one of the four patients (patient 2),
microscopic findings showed central necrosis and viable
cancer cells existed in the periphery of the tumor without
surrounding fibrotic tissue caused by SBRT. In patient 3,
microscopic findings showed that viable cancer cells were
present in the center of the tumor, but one fifth of the
circumference of the tumor was not surrounded by fibrotic
tissue caused by SBRT.
The postoperative clinical course was uneventful in all
patients. The median follow-up time was 27 months. All five
patients are well, alive, and without any apparent tumor
recurrences, including three patients who were followed up
for more than 2 years after salvage surgery.
DISCUSSION
No adverse effect by SBRT was confirmed at the time
of salvage surgery in our patients. Because the irradiated area
was mainly confined to the peripheral lungs, central pulmo-
nary structures such as the hilum were intact after irradiation.
There was also almost no pleural adhesion related to the
irradiation of the peripheral lung tissue including the tumor.
It should be emphasized that surgery was performed without
FIGURE 2. Pathologic findings (patient 1). A, (i) Cut sur-
face of the resected lung after formalin fixation and (ii)
loupe view showing a well-demarcated yellow-white nodular
mass (arrowhead) in the center of fibrotic tissue caused by
stereotactic body radiotherapy (SBRT) (dashed-line area). B,
Microscopic appearance in the boundary area between a
viable tumor nest (right lower area) and surrounding fibrotic
tissue (left upper area). The field corresponds to the square in (A).
TABLE 2. Patient Characteristics at Surgery
Patients
Interval between SBRT
and Surgery Surgical Procedure
yp-TNM
Stage Tumor Size (mm) Histology Outcomes
1 10 mo Left upper lobectomy T2N0M0 34 SQ Alive for 25 mo
2 12 mo Right upper lobectomy T2N0M0 50 SQ Alive for 31 mo
3 104 mo Right upper lobectomy T1N0M0 25 AD Alive for 29 mo
4 17 mo Left upper lobectomy T2N0M0 33 LCNEC Alive for 4 mo
5 21 mo Right upper lobectomy T1N0M0 28 SQ Alive for 2 mo
AD, adenocarcinoma; LCNEC, large cell neuroendocrine carcinoma; SQ, squamous cell carcinoma; SBRT, stereotactic body radiotherapy.
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complications, and postoperative course was also uncom-
plicated in all cases. Despite the small number of cases, we
could for the first time confirm the points that most
surgeons consider before performing surgical extirpation
in such patients.
In this study, four patients relapsed within a relatively
short time after SBRT. Considering that the tumor shrank
after SBRT in these patients, SBRT had some effect on the
tumor, but it is most likely that some residual tumor cells
elapsed within a relatively short time after SBRT. To be more
specific, in three of four patients whose tumor increased in
size again within 18 months after SBRT, pathologic findings
revealed viable cancer cells in the center of the tumor,
surrounded by the fibrotic tissue caused by SBRT. These
findings strongly suggested that the tumor relapsed in the
central portion of the irradiated area, where the effect of
SBRT theoretically tended to decrease because of the hypoxic
environment of the tissue.5,6 On the other hand, in one of four
patients, microscopic examination of the tumor showed cen-
tral necrosis and peripherally located viable cancer cell with-
out surrounding tissue fibrosis caused by SBRT. These find-
ings implied that dose to the tumor was insufficient at the
center for the former three patients and at the periphery for
the latter one. Two potential causes for the dose insufficiency
were supposed: shortage in the planned dose and setup errors
during the treatment. Optimization of dose prescription and
setup correction are needed to improve local control after
lung SBRT. The remaining one patient (patient 3) was unique
in that the tumor relapsed very late after SBRT. Although the
histologic diagnosis before SBRT was not obtained in this
case, the second primary lung cancer, including radiation-
induced carcinoma, might be more likely than recurrence of
the primary lung cancer because of the relatively long dis-
ease-free period.7 In this respect, long-term follow-up might
be advised in this patient population, even beyond 5 years.
Serial measurements of the pulmonary function after
SBRT also reportedly showed no significant decreases in
several parameters including FEV1, as in this study.8 In the
current series, all five operable patients tolerated lung resec-
tion even after SBRT. Several randomized clinical trials
comparing SBRT with surgery have been initiated,9,10 and the
results of these studies might pave the way to further under-
stand SBRT as a method in the multimodality treatment.
Despite a small number of cases, the findings of our study
might be particularly relevant for these trials in operable
patients. By contrast, the current low morbidity and mortality
for lobectomy, especially video-assisted thoracoscopic lobec-
tomy in elderly patients have enabled us to consider surgery
confidently.11 In this situation, the use of SBRT in patients
who are medically fit for surgery should be decided more
carefully.
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